

Hkon Reikvam

List of Publications by Citations

Source: <https://exaly.com/author-pdf/210249/hakon-reikvam-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

101
papers

1,491
citations

24
h-index

33
g-index

119
ext. papers

1,915
ext. citations

4.1
avg, IF

4.9
L-index

#	Paper	IF	Citations
101	Thrombelastography. <i>Transfusion and Apheresis Science</i> , 2009 , 40, 119-23	2.4	113
100	Therapeutic targeting the cell division cycle 25 (CDC25) phosphatases in human acute myeloid leukemia--the possibility to target several kinases through inhibition of the various CDC25 isoforms. <i>Molecules</i> , 2014 , 19, 18414-47	4.8	57
99	The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	55
98	Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications. <i>Journal of Biomedicine and Biotechnology</i> , 2011 , 2011, 104631		48
97	Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. <i>European Journal of Haematology</i> , 2010 , 84, 239-51	3.8	42
96	The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells. <i>Stem Cell Research</i> , 2015 , 15, 530-541	1.6	41
95	Nuclear factor-kappaB signaling: a contributor in leukemogenesis and a target for pharmacological intervention in human acute myelogenous leukemia. <i>Critical Reviews in Oncogenesis</i> , 2009 , 15, 1-41	1.3	39
94	Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells. <i>Oncotarget</i> , 2013 , 4, 830-43	3.3	39
93	The chemokine network in acute myelogenous leukemia: molecular mechanisms involved in leukemogenesis and therapeutic implications. <i>Current Topics in Microbiology and Immunology</i> , 2010 , 341, 149-72	3.3	36
92	Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status--consequences and potentials for pharmacological intervention. <i>British Journal of Haematology</i> , 2012 , 156, 468-80	4.5	35
91	The angioregulatory cytokine network in human acute myeloid leukemia - from leukemogenesis via remission induction to stem cell transplantation. <i>European Cytokine Network</i> , 2012 , 23, 140-53	3.3	34
90	Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect. <i>British Journal of Haematology</i> , 2014 , 164, 200-11	4.5	33
89	Targeted therapy in acute myeloid leukaemia: current status and future directions. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 433-55	5.9	31
88	Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: immunological mechanisms and the results from clinical studies. <i>Cancer Immunology, Immunotherapy</i> , 2014 , 63, 757-77	7.4	29
87	Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment. <i>American Journal of Hematology</i> , 2012 , 87, 368-76	7.1	28
86	Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 169-83	5.9	28
85	Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells. <i>Signal Transduction and Targeted Therapy</i> , 2019 , 4, 20	2.1	26

84	Altered plasma levels of cytokines, soluble adhesion molecules and matrix metalloproteases in venous thrombosis. <i>Thrombosis Research</i> , 2015 , 136, 30-9	8.2	26
83	Cytokines, Adhesion Molecules, and Matrix Metalloproteases as Predisposing, Diagnostic, and Prognostic Factors in Venous Thrombosis. <i>Frontiers in Medicine</i> , 2018 , 5, 147	4.9	26
82	The Possible Importance of β Integrins for Leukemogenesis and Chemoresistance in Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	26
81	Therapeutic targeting of leukemic stem cells in acute myeloid leukemia - the biological background for possible strategies. <i>Expert Opinion on Drug Discovery</i> , 2017 , 12, 1053-1065	6.2	26
80	The pretransplantation serum cytokine profile in allogeneic stem cell recipients differs from healthy individuals, and various profiles are associated with different risks of posttransplantation complications. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 190-9	4.7	26
79	The Mirasol Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution. <i>Blood Transfusion</i> , 2010 , 8, 186-92	3.6	26
78	The possible diagnostic and prognostic use of systemic chemokine profiles in clinical medicine—the experience in acute myeloid leukemia from disease development and diagnosis via conventional chemotherapy to allogeneic stem cell transplantation. <i>Toxins</i> , 2013 , 5, 336-62	4.9	24
77	Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2013 , 22, 551-63	5.9	24
76	The pretransplant systemic metabolic profile reflects a risk of acute graft versus host disease after allogeneic stem cell transplantation. <i>Metabolomics</i> , 2016 , 12, 12	4.7	22
75	Bacterial contamination of blood components: Norwegian strategies in identifying donors with higher risk of inducing septic transfusion reactions in recipients. <i>Transfusion and Apheresis Science</i> , 2014 , 51, 97-102	2.4	22
74	A Subset of Patients with Acute Myeloid Leukemia Has Leukemia Cells Characterized by Chemokine Responsiveness and Altered Expression of Transcriptional as well as Angiogenic Regulators. <i>Frontiers in Immunology</i> , 2016 , 7, 205	8.4	22
73	Effects of cytarabine on activation of human T cells - cytarabine has concentration-dependent effects that are modulated both by valproic acid and all-trans retinoic acid. <i>BMC Pharmacology & Toxicology</i> , 2015 , 16, 12	2.6	20
72	Targeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?. <i>Expert Opinion on Investigational Drugs</i> , 2012 , 21, 587-603	5.9	20
71	Febrile Neutropenia in Acute Leukemia. Epidemiology, Etiology, Pathophysiology and Treatment. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020 , 12, e2020009	3.2	19
70	Pretransplant Levels of CRP and Interleukin-6 Family Cytokines; Effects on Outcome after Allogeneic Stem Cell Transplantation. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	18
69	Splenic tyrosine kinase (SYK) inhibitors and their possible use in acute myeloid leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 377-387	5.9	17
68	The importance of sample collection when using single cytokine levels and systemic cytokine profiles as biomarkers--a comparative study of serum versus plasma samples. <i>Journal of Immunological Methods</i> , 2015 , 418, 19-28	2.5	17
67	Identification of a subset of patients with acute myeloid leukemia characterized by long-term in vitro proliferation and altered cell cycle regulation of the leukemic cells. <i>Expert Opinion on Therapeutic Targets</i> , 2014 , 18, 1237-51	6.4	17

66	Patients with acute myeloid leukemia can be subclassified based on the constitutive cytokine release of the leukemic cells; the possible clinical relevance and the importance of cellular iron metabolism. <i>Expert Opinion on Therapeutic Targets</i> , 2017 , 21, 357-369	6.4	16
65	Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells. <i>BMC Cancer</i> , 2017 , 17, 630	4.8	16
64	Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	16
63	High Constitutive Cytokine Release by Primary Human Acute Myeloid Leukemia Cells Is Associated with a Specific Intercellular Communication Phenotype. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	16
62	Systemic levels of the endothelium-derived soluble adhesion molecules endocan and E-selectin in patients with suspected deep vein thrombosis. <i>SpringerPlus</i> , 2014 , 3, 571		14
61	A prospective observational study of the effect of platelet transfusions on levels of platelet-derived cytokines, chemokines and interleukins in acute leukaemia patients with severe chemotherapy-induced cytopenia. <i>European Cytokine Network</i> , 2011 , 22, 52-62	3.3	14
60	Bronchiolitis obliterans syndrome in adults after allogeneic stem cell transplantation-pathophysiology, diagnostics and treatment. <i>Expert Review of Clinical Immunology</i> , 2017 , 13, 553-569	5.1	13
59	Trisomy 8 in acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2019 , 12, 947-958	2.8	13
58	Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication. <i>Expert Review of Hematology</i> , 2015 , 8, 299-313	2.8	13
57	Soluble mediators released by acute myeloid leukemia cells increase capillary-like networks. <i>European Journal of Haematology</i> , 2012 , 89, 478-90	3.8	13
56	Clonal Heterogeneity Reflected by PI3K-AKT-mTOR Signaling in Human Acute Myeloid Leukemia Cells and Its Association with Adverse Prognosis. <i>Cancers</i> , 2018 , 10,	6.6	13
55	Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation. <i>Oncotarget</i> , 2015 , 6, 2794-811	3.3	12
54	Targeting Cellular Metabolism in Acute Myeloid Leukemia and The Role of Patient Heterogeneity. <i>Cells</i> , 2020 , 9,	7.9	11
53	The effects of selective serotonin reuptake inhibitors on platelet function in whole blood and platelet concentrates. <i>Platelets</i> , 2012 , 23, 299-308	3.6	11
52	Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison. <i>Expert Opinion on Therapeutic Targets</i> , 2018 , 22, 639-653	6.4	10
51	Preconditioning serum levels of endothelial cell-derived molecules and the risk of posttransplant complications in patients treated with allogeneic stem cell transplantation. <i>Journal of Transplantation</i> , 2014 , 2014, 404096	2.3	10
50	Targeted Anti-leukemic Therapy as Disease-stabilizing Treatment for Acute Myeloid Leukemia Relapse after Allogeneic Stem Cell Transplantation: Will it be Possible to Combine these Strategies with Retransplantation or Donor Lymphocyte Infusions?. <i>Current Cancer Drug Targets</i> , 2013 , 13, 30-47	2.8	10
49	Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. <i>Expert Opinion on Investigational Drugs</i> , 2019 , 28, 411-420	5.9	9

48	Comparison of in vitro responses to fresh whole blood and reconstituted whole blood after collagen stimulation. <i>Blood Transfusion</i> , 2014 , 12, 50-5	3.6	9
47	Hyperferritinemia-A Clinical Overview. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	9
46	Emerging therapeutic targets in human acute myeloid leukemia (part 2) - bromodomain inhibition should be considered as a possible strategy for various patient subsets. <i>Expert Review of Hematology</i> , 2015 , 8, 315-27	2.8	8
45	Metabolic Serum Profiles for Patients Receiving Allogeneic Stem Cell Transplantation: The Pretransplant Profile Differs for Patients with and without Posttransplant Capillary Leak Syndrome. <i>Disease Markers</i> , 2015 , 2015, 943430	3.2	8
44	Patients with Treatment-Requiring Chronic Graft versus Host Disease after Allogeneic Stem Cell Transplantation Have Altered Metabolic Profiles due to the Disease and Immunosuppressive Therapy: Potential Implication for Biomarkers. <i>Frontiers in Immunology</i> , 2017 , 8, 1979	8.4	7
43	CDC25 Inhibition in Acute Myeloid Leukemia-A Study of Patient Heterogeneity and the Effects of Different Inhibitors. <i>Molecules</i> , 2017 , 22,	4.8	7
42	Heat shock protein 70 - the next chaperone to target in the treatment of human acute myelogenous leukemia?. <i>Expert Opinion on Therapeutic Targets</i> , 2014 , 18, 929-44	6.4	6
41	Nutrition in Allogeneic Stem Cell Transplantation--Clinical Guidelines and Immunobiological Aspects. <i>Current Pharmaceutical Biotechnology</i> , 2016 , 17, 92-104	2.6	6
40	Myeloid Sarcoma after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Successful Consolidation Treatment Approaches in Two Patients. <i>Case Reports in Oncological Medicine</i> , 2018 , 2018, 7697283	0.9	6
39	Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: Will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions?. <i>Current Cancer Drug Targets</i> , 2013 , 13, 30-47	2.8	6
38	Microcirculation and red cell transfusion in patients with sepsis. <i>Transfusion and Apheresis Science</i> , 2017 , 56, 900-905	2.4	5
37	Untangling the intracellular signalling network in cancer--a strategy for data integration in acute myeloid leukaemia. <i>Journal of Proteomics</i> , 2011 , 74, 269-81	3.9	5
36	Thrombosis and thrombocytopenia after HPV vaccination. <i>Journal of Thrombosis and Haemostasis</i> , 2021 ,	15.4	5
35	The healthy donor profile of immunoregulatory soluble mediators is altered by stem cell mobilization and apheresis. <i>Cytotherapy</i> , 2018 , 20, 740-754	4.8	4
34	Non-curative surgery for aortoenteric fistula. <i>Journal of Surgical Case Reports</i> , 2017 , 2017, rjx153	0.6	3
33	Altered Immune Activation and IL-23 Signaling in Response to in Autoimmune Polyendocrine Syndrome Type 1. <i>Frontiers in Immunology</i> , 2017 , 8, 1074	8.4	3
32	Hemophagocytic lymphohistiocytosis and miliary tuberculosis in a previously healthy individual: a case report. <i>Journal of Medical Case Reports</i> , 2020 , 14, 217	1.2	3
31	How should quality of life assessment be integrated in the evaluation of patients with acute myeloid leukemia?. <i>Expert Review of Quality of Life in Cancer Care</i> , 2016 , 1, 373-387		3

30	A patient with maculopapular rash and lichenoid skin damage caused by ponatinib. <i>Journal of International Medical Research</i> , 2020 , 48, 300060520903660	1.4	3
29	Cytokine profiling and post-transfusion haemoglobin increment in patients with haematological diseases. <i>Vox Sanguinis</i> , 2018 , 113, 657-668	3.1	3
28	Critical upper airway obstruction as the first symptom of acute myeloid leukemia - an anesthesiologic reminder. <i>Clinics and Practice</i> , 2020 , 10, 1214	2.4	2
27	Precision medicine for TP53-mutated acute myeloid leukemia. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019 , 4, 263-274	1.6	2
26	Questionnaire-related deferrals in regular blood donors in norway. <i>Journal of Blood Transfusion</i> , 2012 , 2012, 813231		2
25	Immunoglobulin-Storing Histiocytosis: A Case Based Systemic Review. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
24	Therapeutic Use of Valproic Acid and All-Trans Retinoic Acid in Acute Myeloid Leukemia-Literature Review and Discussion of Possible Use in Relapse after Allogeneic Stem Cell Transplantation. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	2
23	Effects of the Autophagy-Inhibiting Agent Chloroquine on Acute Myeloid Leukemia Cells; Characterization of Patient Heterogeneity. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	2
22	Single Cell Signaling Pharmacodynamics in a Phase 1b Trial of the Axl Inhibitor BGB324 in Acute Myeloid Leukemia. <i>Blood</i> , 2016 , 128, 3995-3995	2.2	1
21	Survival Stratification In Acute Myeloid Leukemia By Single Cell Signal Profiling. <i>Blood</i> , 2013 , 122, 2625-2625		1
20	Inhibition of NF- κ B Signaling Alters Acute Myelogenous Leukemia Cell Transcriptomics. <i>Cells</i> , 2020 , 9,	7.9	1
19	Spontaneous Splenic Artery Rupture as the First Symptom of Systemic Amyloidosis. <i>Case Reports in Critical Care</i> , 2021 , 2021, 6676407	1	1
18	p53 Protein Isoform Profiles in AML: Correlation with Distinct Differentiation Stages and Response to Epigenetic Differentiation Therapy. <i>Cells</i> , 2021 , 10,	7.9	1
17	Proteomic Studies of Primary Acute Myeloid Leukemia Cells Derived from Patients Before and during Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid and Valproic Acid. <i>Cancers</i> , 2021 , 13,	6.6	1
16	Platelet Microparticles Protect Acute Myelogenous Leukemia Cells against Daunorubicin-Induced Apoptosis. <i>Cancers</i> , 2021 , 13,	6.6	1
15	Chronic Myeloid Leukemia Relapsing 25 Years after Allogeneic Stem Cell Transplantation. <i>Case Reports in Hematology</i> , 2018 , 2018, 2045985	0.7	1
14	Pure Red Cell Aplasia with Del(20q) Sensitive for Immunosuppressive Treatment. <i>Case Reports in Hematology</i> , 2020 , 2020, 1262038	0.7	0
13	Intermediate-High Risk Pulmonary Embolism: The Use of Riociguat and Inferior Vena Cava Filter in a Situation of Recurrent Embolism Following Insufficient Anticoagulation and Fibrinolytic Therapy. <i>Case Reports in Anesthesiology</i> , 2020 , 2020, 4219616	0.5	0

12	Successful eradication of leptomenigeal plasma cell disease. <i>Oxford Medical Case Reports</i> , 2018 , 2018, omy038	0.6	o
11	Proteomic Characterization of Spontaneous Stress-Induced In Vitro Apoptosis of Human Acute Myeloid Leukemia Cells; Focus on Patient Heterogeneity and Endoplasmic Reticulum Stress. <i>Hemato</i> , 2021 , 2, 607-627	0.2	o
10	Concomitant Hemophagocytic Lymphohistiocytosis and Cytomegalovirus Disease: A Case Based Systemic Review.. <i>Frontiers in Medicine</i> , 2022 , 9, 819465	4.9	o
9	Mondor's disease after extensive training with Nordic walking. <i>Oxford Medical Case Reports</i> , 2019 , 2019, omz075	0.6	
8	Severe nephritis as initial sign of Waldenström's macroglobulinemia. <i>Clinics and Practice</i> , 2019 , 9, 1184	2.4	
7	Single Cell-Level Signaling Profiling of Acute Myeloid Leukemia Following Treatment with Axl Kinase Inhibitor BGB324. <i>Blood</i> , 2015 , 126, 4931-4931	2.2	
6	Myeloproliferative neoplasms and JAK2 mutations. <i>Tidsskrift for Den Norske Laegeforening</i> , 2016 , 136, 1889-1894	3.5	
5	Surgical Treatment of Severe Bowel Obstruction as a Rare Complication Following Allogenic Hematopoietic Stem Cell Transplantation. <i>Transplantology</i> , 2020 , 1, 102-110	1	
4	Kidney Failure and Abdominal Discomfort as Initial Signs of Extramedullary Acute Myelogenous Leukemia. <i>Clinics and Practice</i> , 2021 , 11, 459-466	2.4	
3	Future perspective: metabolism as a therapeutic target in acute myeloid leukemia - from Warburg to precision medicine. <i>Current Medical Research and Opinion</i> , 2021 , 37, 2107-2111	2.5	
2	Favorable outcome of a patient with an unclassifiable myelodysplastic syndrome/myeloproliferative neoplasm treated with allogeneic hematopoietic stem cell transplantation. <i>SAGE Open Medical Case Reports</i> , 2021 , 9, 2050313X20988413	0.7	
1	Basosquamous Basal Cell Carcinoma with Bone Marrow Metastasis.. <i>Current Oncology</i> , 2022 , 29, 2193-2198		